Takayasu arteritis (TAK) refractory to conventional disease-modifying anti-rheumatic drugs
(DMARDs) is commonly treated with biologic DMARDs such as tocilizumab or tumor …

The term “vasculitis” refers to a group of rare immune‐mediated diseases characterized by
the dysregulated immune system attacking blood vessels located in any organ of the body …

Objectives To update the EULAR recommendations for the use of imaging modalities in
primary large vessel vasculitis (LVV). Methods A systematic literature review update was …

Vasculitis is an inflammation of the blood vessels caused by autoimmunity and/or
autoinflammation, and recent advances in research have led to a better understanding of its …

Arterial wall damage in Takayasu arteritis (TAK) can progress despite immunosuppressive
therapy. Vascular fibrosis is more prominent in TAK than in giant cell arteritis (GCA). The …

Loss of function of inhibitory immune checkpoints, unleashing pathogenic immune
responses, is a potential risk factor for autoimmune disease. Here, we report that patients …

Objectives To investigate the clinicopathologic features of patients with giant cell arteritis
(GCA) who had thoracic aorta aneurysm or dissection surgery. Methods Patients who had …

Takayasu arteritis (TAK) is a less common large vessel vasculitis where histopathology of
involved arteries is difficult to access except during open surgical procedures. Assessment …

Since the advent of single-cell RNA sequencing (scRNA-seq) methodology, single-cell
analysis has become a powerful tool for exploration of cellular networks and dysregulated …

The Janus kinase (JAK)–STAT signaling pathway is relevant in both Takayasu and giant cell
arteritis (GCA), and the use of JAK inhibitors (JAKi) in arthritis, psoriasis, and inflammatory …